Solving The Head & Neck Cancer Puzzle with Cel-Sci's Geert Kersten

From: Eric Michaels
Series: eHealth Radio Report
Length: 15:58

CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. CEO Geert Kersten has been involved in the pioneering field of cancer immunotherapy for almost two decades and has successfully steered CEL-SCI through many challenging cycles in the biotechnology industry. Read the full description.

Piece Audio

Playing: Solving The Head & Neck Cancer Puzzle with ...
From: Eric Michaels

Ehealthradiosquareicon_small CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally at the end game with an investigational immunotherapy, Multikine® currently being tested in a global Phase III trial.

The firm has taken a rather unconventional path with the ground-breaking treatment, which has gotten the attention of both Wall Street Investors and The National Institute of Health. The drug has been highlighted by several publications recently as one of the most promising new cancer treatments in development and under review by the FDA.

Piece Description

CEL-SCI's story is one of vision, persistence, and survival in the face of overwhelming odds. Despite downturns in the biotech sector, lack of funding, and a lengthy clinical trial process associated with the development of its investigational therapy for advanced primary head and neck cancer, CEL-SCI is finally at the end game with an investigational immunotherapy, Multikine® currently being tested in a global Phase III trial.

The firm has taken a rather unconventional path with the ground-breaking treatment, which has gotten the attention of both Wall Street Investors and The National Institute of Health. The drug has been highlighted by several publications recently as one of the most promising new cancer treatments in development and under review by the FDA.